KIST Transfers ‘Dry Macular Degeneration Peptide Therapy’ Technology to Huons Bio
The Korea Institute of Science and Technology (KIST, President Oh Sang-rok) held a technology transfer signing ceremony on the 17th at the KIST headquarters in Seongbuk-gu, Seoul, with Huons Biopharma (CEO Kim Young-mok) for the development of a peptide therapeutic for dry age-related macular degeneration.
Under this agreement, the two institutions plan to conduct collaborative research over the next 14 months to accelerate the commercialization of peptide therapy technology for dry age-related macular degeneration targeting the elderly.
President Oh Sang-rok stated, “The collaboration between KIST and Huons Biopharma will serve as a representative example of the BP Plus project, which actively supports the commercialization process of companies that have signed technology transfer contracts.”
Kim Young-mok, CEO of Huons Biopharma, said, “We will work closely with KIST to advance global clinical trials for innovative dry age-related macular degeneration drugs and obtain product approval.”
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Like Samsung, Us Too"... Performance Bonus Battle Spreads to Principal and Subcontractor Unions with Yellow Envelope Act
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Huons Biopharma is a subsidiary of the Huons Group engaged in bio-businesses such as botulinum toxin. It was established in 2021 through a spin-off of the bio-business division of Huons Global.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.